{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:14:50Z","timestamp":1793970890643,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>In seizure-naive brain tumor patients, the efficacy of perioperative prophylactic antiepileptic drug treatment remains controversial. In case of administration, the common preferred drug is levetiracetam (LEV) because of its favorable pharmacological profile. Research to date has not sufficiently determined how LEV affects cognition in the short term, as is the case in the perioperative period. The objective of this prospective study was to examine the neurocognitive functioning of seizure-naive brain tumor patients after receiving LEV perioperatively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fortythree patients with supratentorial brain tumor scheduled for surgery received LEV three days before until six days after surgery as seizure prophylaxis. Cognitive functioning (NeuroCogFX), LEV plasma-levels, hematotoxicity, side-effects, as well as health-related quality of life (HRQoL, Qolie31), were recorded preoperatively before (Baseline) and after onset of LEV (Pre-Op), 4\u20136\u00a0days postoperatively (Post-Op) and 21\u00a0days postoperatively (Follow-Up).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No significant changes in cognitive functioning and HRQoL were seen after onset of preoperative LEV. There was a significant improvement of NeuroCogFX total-score at Follow-Up (<jats:italic>p<\/jats:italic>\u2009=\u20090.004) compared to Baseline. The overall-score Qolie31 showed simultaneous improvement patterns as cognitive functioning (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The most frequent side effect related to study drug was somnolence (in 28.6% of patients).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A significant improvement of cognitive functioning, as well as an improvement in HRQoL, were detected postoperatively. This is presumably due to the debulking effect of the surgery. Nevertheless, LEV has no detrimental effect on cognitive functioning in the perioperative phase in seizure-naive brain tumor patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study was registered prospectively (Date: 25\/11\/2015; EudraCT: 2015\u2013003,916-19).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02762-7","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T07:03:33Z","timestamp":1657263813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-585X","authenticated-orcid":false,"given":"Elias","family":"Konrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-8060","authenticated-orcid":false,"given":"Franz","family":"Marhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scheichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Popadic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Blauensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Calabek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Freydl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ristl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Oberndorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"2762_CR1","doi-asserted-by":"crossref","unstructured":"Walbert, T., et al., SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol, 2021.","DOI":"10.1093\/neuonc\/noab152"},{"key":"2762_CR2","doi-asserted-by":"crossref","unstructured":"Greenhalgh, J., et al., Antiepileptic drugs as prophylaxis for postcraniotomy seizures. Cochrane Database Syst Rev, 2020. 4: p. CD007286.","DOI":"10.1002\/14651858.CD007286.pub5"},{"key":"2762_CR3","doi-asserted-by":"crossref","unstructured":"Glantz, M.J., et al., Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000. 54(10): p. 1886\u201393.","DOI":"10.1212\/WNL.54.10.1886"},{"issue":"2","key":"2762_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10143-016-0771-2","volume":"40","author":"G Spena","year":"2017","unstructured":"Spena G, et al. Brain tumors in eloquent areas: A European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis. Neurosurg Rev. 2017;40(2):287\u201398.","journal-title":"Neurosurg Rev"},{"issue":"6","key":"2762_CR5","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3171\/2016.4.JNS16245","volume":"126","author":"MC Dewan","year":"2017","unstructured":"Dewan MC, et al. Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS\/CNS Section on Tumors survey. J Neurosurg. 2017;126(6):1772\u20138.","journal-title":"J Neurosurg"},{"key":"2762_CR6","doi-asserted-by":"crossref","unstructured":"Yoon, H.I., et al., The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1. Brain Tumor Research and Treatment, 2021. 9(1): p. 1.","DOI":"10.14791\/btrt.2021.9.e8"},{"issue":"5","key":"2762_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","volume":"6","author":"MSM van Breemen","year":"2007","unstructured":"van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. The Lancet Neurology. 2007;6(5):421\u201330.","journal-title":"The Lancet Neurology"},{"key":"2762_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/B978-0-12-802997-8.00016-5","volume":"134","author":"DJ Englot","year":"2016","unstructured":"Englot DJ, Chang EF, Vecht CJ. Epilepsy and brain tumors. Handb Clin Neurol. 2016;134:267\u201385.","journal-title":"Handb Clin Neurol"},{"key":"2762_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104786","volume":"156","author":"F Cucchiara","year":"2020","unstructured":"Cucchiara F, et al. Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours? Pharmacol Res. 2020;156: 104786.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2762_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11060-018-2941-2","volume":"140","author":"AI Islim","year":"2018","unstructured":"Islim AI, et al. Postoperative seizures in meningioma patients: improving patient selection for antiepileptic drug therapy. J Neurooncol. 2018;140(1):123\u201334.","journal-title":"J Neurooncol"},{"issue":"6","key":"2762_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3171\/2017.2.JNS162315","volume":"128","author":"S Oushy","year":"2018","unstructured":"Oushy S, et al. New-onset seizure during and after brain tumor excision: a risk assessment analysis. J Neurosurg. 2018;128(6):1713\u20138.","journal-title":"J Neurosurg"},{"issue":"9","key":"2762_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/01.wnl.0000324624.52935.46","volume":"71","author":"TA Milligan","year":"2008","unstructured":"Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008;71(9):665\u20139.","journal-title":"Neurology"},{"issue":"10","key":"2762_CR13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/jnnp-2014-308584","volume":"86","author":"T Iuchi","year":"2015","unstructured":"Iuchi T, et al. Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. J Neurol Neurosurg Psychiatry. 2015;86(10):1158\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2762_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3171\/2015.10.JNS151956","volume":"125","author":"MC Dewan","year":"2016","unstructured":"Dewan MC, et al. Perioperative seizure in patients with glioma is associated with longer hospitalization, higher readmission, and decreased overall survival. J Neurosurg. 2016;125(4):1033\u201341.","journal-title":"J Neurosurg"},{"issue":"4","key":"2762_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/neuros\/nyw106","volume":"80","author":"MC Dewan","year":"2017","unstructured":"Dewan MC, et al. The Influence of Perioperative Seizure Prophylaxis on Seizure Rate and Hospital Quality Metrics Following Glioma Resection. Neurosurgery. 2017;80(4):563\u201370.","journal-title":"Neurosurgery"},{"issue":"1","key":"2762_CR16","doi-asserted-by":"publisher","first-page":"13674","DOI":"10.1038\/s41598-020-70754-z","volume":"10","author":"TF Ersoy","year":"2020","unstructured":"Ersoy TF, et al. Early postoperative seizures (EPS) in patients undergoing brain tumour surgery. Sci Rep. 2020;10(1):13674.","journal-title":"Sci Rep"},{"issue":"5","key":"2762_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/jnnp-2018-319609","volume":"90","author":"C Mirian","year":"2019","unstructured":"Mirian C, et al. Antiepileptic drugs as prophylaxis for de novo brain tumour-related epilepsy after craniotomy: a systematic review and meta-analysis of harm and benefits. J Neurol Neurosurg Psychiatry. 2019;90(5):599\u2013607.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2762_CR18","first-page":"1","volume":"130","author":"CH Lee","year":"2019","unstructured":"Lee CH, et al. Phenytoin versus levetiracetam as prophylaxis for postcraniotomy seizure in patients with no history of seizures: systematic review and meta-analysis. J Neurosurg. 2019;130(6):1\u20138.","journal-title":"J Neurosurg"},{"issue":"1","key":"2762_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1528-1167.2012.03563.x","volume":"54","author":"KL Fuller","year":"2013","unstructured":"Fuller KL, et al. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. Epilepsia. 2013;54(1):45\u201357.","journal-title":"Epilepsia"},{"issue":"1","key":"2762_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00415-014-7552-z","volume":"262","author":"A Tinchon","year":"2015","unstructured":"Tinchon A, et al. Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. J Neurol. 2015;262(1):179\u201386.","journal-title":"J Neurol"},{"issue":"1","key":"2762_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bcp.12926","volume":"82","author":"C Pourzitaki","year":"2016","unstructured":"Pourzitaki C, et al. Efficacy and safety of prophylactic levetiracetam in supratentorial brain tumour surgery: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(1):315\u201325.","journal-title":"Br J Clin Pharmacol"},{"key":"2762_CR22","doi-asserted-by":"crossref","unstructured":"Rossetti, A.O., et al., Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro Oncol, 2014. 16(4): p. 584\u20138.","DOI":"10.1093\/neuonc\/not170"},{"key":"2762_CR23","doi-asserted-by":"crossref","unstructured":"Mbizvo, G.K., et al., Levetiracetam add-on for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews, 2020. 2020(6).","DOI":"10.1002\/14651858.CD001901.pub3"},{"issue":"3","key":"2762_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11060-008-9781-4","volume":"93","author":"DA Lim","year":"2009","unstructured":"Lim DA, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol. 2009;93(3):349\u201354.","journal-title":"J Neurooncol"},{"issue":"2","key":"2762_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1755-5949.2008.00062.x","volume":"15","author":"SA Hamed","year":"2009","unstructured":"Hamed SA. The aspects and mechanisms of cognitive alterations in epilepsy: the role of antiepileptic medications. CNS Neurosci Ther. 2009;15(2):134\u201356.","journal-title":"CNS Neurosci Ther"},{"key":"2762_CR26","doi-asserted-by":"crossref","unstructured":"Helmstaedter, C. and J.-A. Witt, Anticonvulsant Drugs and Cognition, in NeuroPsychopharmacotherapy. 2020. p. 1\u201312.","DOI":"10.1007\/978-3-319-56015-1_375-1"},{"issue":"1","key":"2762_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12410","volume":"28","author":"E Bergo","year":"2019","unstructured":"Bergo E, et al. Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature. Eur J Cancer Care (Engl). 2019;28(1): e12410.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"2762_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1474-4422(04)00680-5","volume":"3","author":"MJB Taphoorn","year":"2004","unstructured":"Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. The Lancet Neurology. 2004;3(3):159\u201368.","journal-title":"The Lancet Neurology"},{"issue":"6","key":"2762_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2340\/16501977-1975","volume":"47","author":"EM van Loon","year":"2015","unstructured":"van Loon EM, et al. Assessment methods and prevalence of cognitive dysfunction in patients with low-grade glioma: A systematic review. J Rehabil Med. 2015;47(6):481\u20138.","journal-title":"J Rehabil Med"},{"issue":"3","key":"2762_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.yebeh.2007.02.007","volume":"10","author":"B Gomer","year":"2007","unstructured":"Gomer B, et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav. 2007;10(3):486\u201394.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"2762_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.eplepsyres.2005.10.006","volume":"68","author":"A Piazzini","year":"2006","unstructured":"Piazzini A, et al. Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res. 2006;68(3):181\u20138.","journal-title":"Epilepsy Res"},{"issue":"5","key":"2762_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1440-1819.2008.01848.x","volume":"62","author":"CW Huang","year":"2008","unstructured":"Huang CW, Pai MC, Tsai JJ. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry Clin Neurosci. 2008;62(5):548\u201353.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1\u20132","key":"2762_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yebeh.2010.02.011","volume":"18","author":"C Helmstaedter","year":"2010","unstructured":"Helmstaedter C, Witt J-A. Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial. Epilepsy Behav. 2010;18(1\u20132):74\u201380.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"2762_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/neuonc\/nos288","volume":"15","author":"M de Groot","year":"2013","unstructured":"de Groot M, et al. Levetiracetam improves verbal memory in high-grade glioma patients. Neuro Oncol. 2013;15(2):216\u201323.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2762_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.9758\/cpn.2015.13.1.83","volume":"13","author":"JC Magalhaes","year":"2015","unstructured":"Magalhaes JC, et al. The influence of levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach. Clin Psychopharmacol Neurosci. 2015;13(1):83\u201393.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"42","key":"2762_CR36","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.2174\/1381612823666171024154851","volume":"23","author":"DR Calnan","year":"2017","unstructured":"Calnan DR, et al. Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions. Curr Pharm Des. 2017;23(42):6399\u2013410.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"2762_CR37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.yebeh.2009.07.041","volume":"16","author":"C Hoppe","year":"2009","unstructured":"Hoppe C, et al. NeuroCog FX: computerized screening of cognitive functions in patients with epilepsy. Epilepsy Behav. 2009;16(2):298\u2013310.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"2762_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1212\/WNL.55.2.236","volume":"55","author":"J Cereghino","year":"2000","unstructured":"Cereghino J, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236\u201342.","journal-title":"Neurology"},{"key":"2762_CR39","unstructured":"Health, U.D.o. and H. Services, Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Published November 27, 2017. 2019."},{"issue":"3","key":"2762_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11060-010-0194-9","volume":"100","author":"K Fliessbach","year":"2010","unstructured":"Fliessbach K, et al. Computer-based assessment of cognitive functions in brain tumor patients. J Neurooncol. 2010;100(3):427\u201337.","journal-title":"J Neurooncol"},{"issue":"1","key":"2762_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","volume":"39","author":"JA Cramer","year":"1998","unstructured":"Cramer JA, et al. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia. 1998;39(1):81\u20138.","journal-title":"Epilepsia"},{"issue":"2","key":"2762_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11060-010-0126-8","volume":"99","author":"JB Usery","year":"2010","unstructured":"Usery JB, et al. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol. 2010;99(2):251\u201360.","journal-title":"J Neurooncol"},{"issue":"1","key":"2762_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-010-0460-x","volume":"104","author":"M Maschio","year":"2011","unstructured":"Maschio M, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol. 2011;104(1):205\u201314.","journal-title":"J Neurooncol"},{"issue":"2","key":"2762_CR44","first-page":"131","volume":"7","author":"R Sinha","year":"2020","unstructured":"Sinha R, Stephenson JM, Price SJ. A systematic review of cognitive function in patients with glioblastoma undergoing surgery. Neurooncol Pract. 2020;7(2):131\u201342.","journal-title":"Neurooncol Pract"},{"issue":"4","key":"2762_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/nop\/npw030","volume":"4","author":"M Dallabona","year":"2017","unstructured":"Dallabona M, et al. Impact of mass effect, tumor location, age, and surgery on the cognitive outcome of patients with high-grade gliomas: a longitudinal study. Neuro-Oncology Practice. 2017;4(4):229\u201340.","journal-title":"Neuro-Oncology Practice"},{"issue":"8","key":"2762_CR46","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00701-014-2115-8","volume":"156","author":"EJ Habets","year":"2014","unstructured":"Habets EJ, et al. Tumour and surgery effects on cognitive functioning in high-grade glioma patients. Acta Neurochir (Wien). 2014;156(8):1451\u20139.","journal-title":"Acta Neurochir (Wien)"},{"issue":"8","key":"2762_CR47","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/neuonc\/nov065","volume":"17","author":"F Campanella","year":"2015","unstructured":"Campanella F, et al. Acute effects of surgery on emotion and personality of brain tumor patients: surgery impact, histological aspects, and recovery. Neuro Oncol. 2015;17(8):1121\u201331.","journal-title":"Neuro Oncol"},{"issue":"3","key":"2762_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11060-019-03259-z","volume":"144","author":"EJ Habets","year":"2019","unstructured":"Habets EJ, et al. Association between tumor location and neurocognitive functioning using tumor localization maps. J Neurooncol. 2019;144(3):573\u201382.","journal-title":"J Neurooncol"},{"issue":"2","key":"2762_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/jnnp.73.2.116","volume":"73","author":"S Wiebe","year":"2002","unstructured":"Wiebe S, et al. Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry. 2002;73(2):116\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02762-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02762-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02762-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T08:15:07Z","timestamp":1657268107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02762-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2762"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02762-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"5 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study\u2014approved by the Ethics Committee of Lower Austria (GS1-EK-2\/342\u20132015)\u2014was conducted in accordance with the current version of the Declaration of Helsinki. Informed consent for participation and publication was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors\u00a0consent to the\u00a0publication in BMC Neurology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}